The DiaMonD study provides evidence to challenge common misperceptions about CGM use in patients on MDI.
The Comisair study shows that CGM drives HbA1c reduction, despite the insulin delivery method.
This study examines the impact of the Dexcom G5® Mobile CGM System use in patients on multiple daily injections (MDI) insulin therapy with a history of SH or IHA.
In addition to the DIaMonD study, the GOLD study presents convincing evidence of glycaemic improvements in patients on MDI therapy and is the first major study to show improvements in key quality of life measures.
Now you can get all the latest news and updates of our products, events and resources right into your inbox.
We are always happy to help, send us a message or enquiry
